WEST Search History

DATE: Thursday, July 17, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB; PLUR=YES; OP=ADJ			
L13	L12 and l3	4	L13
L12	rip14 or rip-14	· 8	L12
L11	rip[14 or rip-14	2	L11
L10	L9 and l3	18	L10
L9	bile acid receptor	28	L9
L8	L6 and l3	1	L8
L7	L6 and l1	0	L7
L6	nr1h4	13	L6
L5	L4 and l3	29	L5
L4	fxr	155	L4
L3	antisense or anti-sense	32368	L3
L2	L1	19468	L2
DB=USPT; PLUR=YES; OP=ADJ			
L1	antisense or anti-sense	19468	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International!   Enter x:x

LOGINID:SSSPTA1805SXM

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

NEWS   1   Web Page URLs for STN Seminar Schedule - N. America
NEWS   2   "Ask CAS" for self-help around the clock
NEWS   3   Feb 24   PCTGEN now available on STN
NEWS   4   Feb 24   TEMA now available on STN
NEWS   5   Feb 26   NTIS now allows simultaneous left and right truncation
NEWS   6   Feb 26   PCTFULL now contains images
NEWS   7   Mar 04   SDI PACKAGE for monthly delivery of multifile SDI results
NEWS   8   Mar 24   PATDPAFULL now available on STN
NEWS   9   Mar 24   Additional information for trade-named substances without
                      structures available in REGISTRY
NEWS 10   Apr 11   Display formats in DGENE enhanced
NEWS 11   Apr 14   MEDLINE Reload
NEWS 12   Apr 17   Polymer searching in REGISTRY enhanced
NEWS 13   Jun 13   Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14   Apr 21   New current-awareness alert (SDI) frequency in
                      WPIDS/WPINDEX/WPIX
NEWS 15   Apr 28   RDISCLOSURE now available on STN
NEWS 16   May 05   Pharmacokinetic information and systematic chemical names
                      added to PHAR
NEWS 17   May 15   MEDLINE file segment of TOXCENTER reloaded
NEWS 18   May 15   Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19   May 19   Simultaneous left and right truncation added to WSCA
NEWS 20   May 19   RAPRA enhanced with new search field, simultaneous left and
                      right truncation
NEWS 21   Jun 06   Simultaneous left and right truncation added to CBNB
NEWS 22   Jun 06   PASCAL enhanced with additional data
NEWS 23   Jun 20   2003 edition of the FSTA Thesaurus is now available
NEWS 24   Jun 25   HSDB has been reloaded
NEWS 25   Jul 16   Data from 1960-1976 added to RDISCLOSURE

NEWS EXPRESS   April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS   STN Operating Hours Plus Help Desk Availability
NEWS INTER   General Internet Information
NEWS LOGIN   Welcome Banner and News Items
NEWS PHONE   Direct Dial and Telecommunication Network Access to STN
NEWS WWW   CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:02:33 ON 17 JUL 2003

=> file medline caplus biotechno biosis scisearch embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 09:03:26 ON 17 JUL 2003

FILE 'CAPLUS' ENTERED AT 09:03:26 ON 17 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 09:03:26 ON 17 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:03:26 ON 17 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 09:03:26 ON 17 JUL 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'EMBASE' ENTERED AT 09:03:26 ON 17 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

```
=> s antisense or anti-sense
L1      124543 ANTISENSE OR ANTI-SENSE

=> s fxr
L2         878 FXR

=> s nr1h14
L3           0 NR1H14

=> s nrih4
L4           0 NRIH4

=> s nr1h4
L5          70 NR1H4

=> s rip14
L6          17 RIP14

=> s rip-14
L7           3 RIP-14

=> s retinoid x receptor-interacting protein
L8          22 RETINOID X RECEPTOR-INTERACTING PROTEIN

=> s bile acid receptor
L9         177 BILE ACID RECEPTOR

=> s l2 or l5 or l6 or l7 or l8 or l9
L10        983 L2 OR L5 OR L6 OR L7 OR L8 OR L9

=> s l10 and l1
L11          3 L10 AND L1

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12          3 DUP REM L11 (0 DUPLICATES REMOVED)
```

=> d 1-3 ab

L12   ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
AB   **Antisense** compds., compns. and methods are provided for
       modulating the expression of human **FXR** (farnesoid X receptor).
       The compns. comprise **antisense** compds., particularly
       antisense oligonucleotides, targeted to nucleic acids encoding
       human **FXR**. Methods of using these compds. for modulation of
       human **FXR** expression and for treatment of cardiovascular disease
       and atherosclerosis assocd. with expression of human **FXR** are
       provided.

L12   ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AB   The present invention relates to a human and mouse novel nuclear receptor
       called "L66" or also **FXR**-.beta. (farnesoid X receptor .beta.), a
       homolog of the **FXR**-.alpha. which is a prototypical type 2
       nuclear receptor. The invention also relates to the isolated nucleic acid
       sequence of L66 and the isolated protein thereof. The invention further
       relates to processes for isolating and/or producing the nucleic acid or
       the protein as well as methods of use of the receptor L66. The invention
       also provides the sequence of mouse gene L66 and reverse complement
       sequence. The invention also relates to screening drugs which are capable
       of inhibiting the cellular function of the nuclear receptor L66 in cells,
       including antibody, RNA, **antisense** oligo and ribozyme. The
       invention also relates to expression of L66 in tissues and cell lines.

L12   ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AB   Fibrosis is a consequence of injury characterized by accumulation of
       excess collagen and other extracellular matrix components, resulting in
       the destruction of normal tissue architecture and loss of function. Sp1
       was originally described as a ubiquitous transcription factor. It is
       involved in the basal expression of extracellular matrix genes and may,
       therefore, be important in fibrotic processes. To evaluate the effect of
       Sp1 blockade on the expression of extracellular matrix genes, clones of
       NIH 3T3 fibroblasts stably transfected with an **anti-
       sense** Sp1 expression vector. Simultaneously reduced expression of
       several extracellular matrix genes as compared with mock-transfected
       clones was noted using differential hybridization of cDNA microarrays,
       without significant alteration in cell growth. Transfection of human
       dermal fibroblasts with several extracellular matrix gene (COL1A1, COL1A2,
       COL3A1, COL5A2, COL7A1, TIMP-1, and decorin) promoter/reporter constructs
       demonstrated that **anti-sense** Sp1-induced redn. of
       extracellular matrix gene mRNA steady-state levels results from
       transcriptional repression, consistent with the role of Sp1 as a
       transcription factor. Decoy Sp1 binding oligonucleotides inhibited COL1A2
       promoter activity both in cultured fibroblasts and in vivo, in the skin of
       transgenic mice, which have integrated a mouse COL1A2 promoter/luciferase
       reporter gene construct. These results indicate that targeting Sp1
       efficiently blocks extracellular matrix gene expression, and suggest that
       such an approach may represent an interesting therapeutic alternative
       toward the treatment of fibrotic disorders.

=> s ribozyme or ribozymes
L13   23191 RIBOZYME OR RIBOZYMES

=> s l10 and l13
L14   1 L10 AND L13

=> l14 not l12
L14 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter

```
=> s 114 not 112
L15              0 L14 NOT L12

=> d 1-3 112
```

```
L12  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS
AN   2003:417857  CAPLUS
DN   139:17574
TI   Use of antisense oligonucleotides to gene encoding human
     farnesoid X receptor for treatment of cardiovascular disease and
     atherosclerosis
IN   Monia, Brett P.; Watt, Andrew T.
PA   Isis Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 127 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2003044167     A2    20030530      WO 2002-US36691  20021113
       W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
           GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
           LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
           PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
           UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
           TJ, TM
       RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
           CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
           PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
           NE, SN, TD, TG
     US 2003109467     A1    20030612      US 2001-2491     20011115
PRAI US 2001-2491      A     20011115
```

```
L12  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:220785  CAPLUS
DN   136:274299
TI   Human and mouse nuclear receptor L66, protein and cDNA sequences and
     recombinant production
IN   Casari, Georg; Hoefer, Michael; Jackson, David; Kranz, Harald; Otte,
     Kerstin; Remmel, Bettina; Suckow, Joerg
PA   Lion Bioscience A.-G., Germany
SO   PCT Int. Appl., 136 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2002022817     A2    20020321      WO 2001-EP10323  20010907
     WO 2002022817     A3    20030327
       W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
           GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
           LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
           RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
           UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
       RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
           DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
           BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002013893     A5    20020326      AU 2002-13893    20010907
```

```
      EP 1317542      A2    20030611       EP 2001-982261    20010907
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI  EP 2000-120370    A    20000916
      EP 2001-111658    A    20010514
      WO 2001-EP10323   W    20010907

L12   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2003 ACS
AN    2001:402491  CAPLUS
DN    135:236379
TI    Blocking Sp1 transcription factor broadly inhibits extracellular matrix
      gene expression in vitro and in vivo: implications for the treatment of
      tissue fibrosis
AU    Verrecchia, Franck; Rossert, Jerome; Mauviel, Alain
CS    INSERM U532, Hopital Saint-Louis, Paris, 75475, Fr.
SO    Journal of Investigative Dermatology (2001), 116(5), 755-763
      CODEN: JIDEAE; ISSN: 0022-202X
PB    Blackwell Science, Inc.
DT    Journal
LA    English
RE.CNT  61     THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
```